Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus TRASICOR.
BRIMONIDINE TARTRATE; TIMOLOL MALEATE vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker